EMPEROR_HFrEF

A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with reduced Ejection Fraction (HFrEF).

Stadium: klaar
Middel: empagliflozin
Populatie: Hartfalen
Fase: III
First Patient In: 25 juli 2017
Last Patient In: 9 september 2019
Last Patient Last Visit: -

Studiedirecteur

dr. R.G.E.J. Groutars

Cardioloog